• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4 filed by Opaleye Management Inc.

    3/26/26 6:57:51 PM ET
    $ACOG
    Get the next $ACOG alert in real time by email
    SEC FORM 4SEC Form 4
    FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number:3235-0287
    Estimated average burden
    hours per response:0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
      
    Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
    1. Name and Address of Reporting Person*
    Opaleye Management Inc.

    (Last)(First)(Middle)
    ONE BOSTON PLACE, 26TH FLOOR

    (Street)
    BOSTON MASSACHUSETTS 02108

    (City)(State)(Zip)

    UNITED STATES

    (Country)
    2. Issuer Name and Ticker or Trading Symbol
    Alpha Cognition Inc. [ ACOG ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    DirectorX10% Owner
    Officer (give title below)Other (specify below)
    2a. Foreign Trading Symbol
    3. Date of Earliest Transaction (Month/Day/Year)
    03/24/2026
    6. Individual or Joint/Group Filing (Check Applicable Line)
    XForm filed by One Reporting Person
    Form filed by More than One Reporting Person
    4. If Amendment, Date of Original Filed (Month/Day/Year)

    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeVAmount(A) or (D)Price
    Common Stock, no par value03/24/2026P4,182A$5.592,444,100IBy Opaleye, L.P.(1)(5)
    Common Stock, no par value03/25/2026P8,581A$5.4281(3)2,452,681IBy Opaleye, L.P.(1)(5)
    Common Stock, no par value03/26/2026P7,319A$5.2842(4)2,460,000IBy Opaleye, L.P.(1)(5)
    Common Stock, no par value90,000IBy Managed Account(2)(5)
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
    Explanation of Responses:
    1. Represents securities owned directly by Opaleye, L.P. (the "Fund"). As the investment manager of the Fund, Opaleye Management Inc. may be deemed to beneficially own the securities owned directly by the Fund.
    2. Securities owned by a separately managed account (the "Managed Account"). As the portfolio manager of the Managed Account, Opaleye may be deemed to beneficially own the securities owned directly by the Managed Account.
    3. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.39 to $5.50. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
    4. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.159 to $5.3243. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares purchased at each separate price within the range.
    5. Opaleye Management Inc. disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein, and the filing of this Form 4 shall not be construed as an admission that Opaleye Management Inc. is the beneficial owner of any such shares for purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or for any other purpose.
    Opaleye Management Inc., By: /s/ James Silverman, President03/26/2026
    ** Signature of Reporting PersonDate
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    * Form 4: SEC 1474 (03-26)
    Get the next $ACOG alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ACOG

    DatePrice TargetRatingAnalyst
    5/29/2026$12.00Buy
    Maxim Group
    4/17/2026$14.00Buy
    Craig Hallum
    3/18/2025$20.00Buy
    H.C. Wainwright
    More analyst ratings

    $ACOG
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

    ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan

    5/14/26 4:15:00 PM ET
    $ACOG

    Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

    Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management

    4/28/26 4:30:00 PM ET
    $ACOG

    Alpha Cognition Inc. to Participate in Three Upcoming Investor Conferences

    Alpha Cognition, Inc. (NASDAQ:ACOG) ("Alpha Cognition", "ACI", or the "Company"), a biopharmaceutical company developing novel therapeutics for debilitating neurodegenerative disorders, today announced that Michael McFadden, Chief Executive Officer, will participate in three investor conferences in May. Event details are as follows: Market Movers Investor Summit Format: Presentation and 1x1 meetings Date/Time: Tuesday, May 5 at 2:40 p.m. ET H.C. Wainwright 4th Annual BioConnect Investor Conference at Nasdaq Format: Fireside Chat and 1x1 meetings Date/Time: Tuesday, May 19 at 4:30 p.m. ET Craig Hallum's 23rd Annual Institutional Investor Conference Format: 1x1 meetings Date: May 28,

    4/27/26 8:00:00 AM ET
    $ACOG

    $ACOG
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $434,714 worth of shares (73,738 units at $5.90) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/29/26 7:21:38 PM ET
    $ACOG

    Large owner Opaleye Management Inc. bought $140,545 worth of shares (24,376 units at $5.77) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/22/26 4:05:27 PM ET
    $ACOG

    Chief Operating Officer D'Angelo Lauren bought $20,160 worth of shares (3,500 units at $5.76), increasing direct ownership by 3% to 140,695 units (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/19/26 5:02:16 PM ET
    $ACOG

    $ACOG
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Opaleye Management Inc. bought $434,714 worth of shares (73,738 units at $5.90) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/29/26 7:21:38 PM ET
    $ACOG

    Large owner Opaleye Management Inc. bought $140,545 worth of shares (24,376 units at $5.77) (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/22/26 4:05:27 PM ET
    $ACOG

    Chief Operating Officer D'Angelo Lauren bought $20,160 worth of shares (3,500 units at $5.76), increasing direct ownership by 3% to 140,695 units (SEC Form 4)

    4 - Alpha Cognition Inc. (0001655923) (Issuer)

    5/19/26 5:02:16 PM ET
    $ACOG

    $ACOG
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.

    SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

    5/22/26 4:05:20 PM ET
    $ACOG

    SEC Form 10-Q filed by Alpha Cognition Inc.

    10-Q - Alpha Cognition Inc. (0001655923) (Filer)

    5/14/26 4:01:44 PM ET
    $ACOG

    Amendment: SEC Form SCHEDULE 13G/A filed by Alpha Cognition Inc.

    SCHEDULE 13G/A - Alpha Cognition Inc. (0001655923) (Subject)

    5/12/26 7:11:10 PM ET
    $ACOG

    $ACOG
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Maxim Group initiated coverage on Alpha Cognition with a new price target

    Maxim Group initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $12.00

    5/29/26 7:48:09 AM ET
    $ACOG

    Craig Hallum initiated coverage on Alpha Cognition with a new price target

    Craig Hallum initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $14.00

    4/17/26 8:03:30 AM ET
    $ACOG

    H.C. Wainwright initiated coverage on Alpha Cognition with a new price target

    H.C. Wainwright initiated coverage of Alpha Cognition with a rating of Buy and set a new price target of $20.00

    3/18/25 7:48:36 AM ET
    $ACOG

    $ACOG
    Leadership Updates

    Live Leadership Updates

    View All

    Alpha Cognition Strengthens Its Board of Directors with Appointment of Bethany Sensenig

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company focused on developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Bethany Sensenig to its Board of Directors, effective April 15, 2026. Ms. Sensenig brings decades of leadership experience across the pharmaceutical and biotechnology industries, with deep expertise in finance, corporate strategy, and operations. "On behalf of the entire Board of Directors, it is a pleasure to welcome Bethany Sensenig, a highly accomplished industry leader," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc. "Her broad experience acro

    4/20/26 5:00:00 PM ET
    $ACOG
    $KALV
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Strengthens Its Leadership Team with Appointment of Robert Wills to Board of Directors and Announces Departure of Existing Director John Havens

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the appointment of Robert Wills, Ph.D., to its Board of Directors, effective immediately April 7, 2025. Dr. Wills brings decades of experience in the pharmaceutical and biotechnology industries, with a distinguished career in drug development, corporate strategy, and executive leadership. "On behalf of the entire Board of Directors, it is a pleasure to welcome Rob, a highly accomplished industry veteran, to our team," said Michael McFadden, Chief Executive Officer of Alpha Cognition, Inc.

    4/10/25 8:30:00 AM ET
    $ACOG
    $CBAY
    $MIST
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Alpha Cognition Expands Commercial and Medical Teams with Key Leadership Hires to Support the Launch of ZUNVEYL

    Alpha Cognition Inc. (NASDAQ:ACOG) ("Alpha Cognition", or the "Company"), a biopharmaceutical company committed to developing novel therapies for debilitating neurodegenerative disorders, today announced the strategic appointments of Jen Pesa, Vice President of Commercial; Jack Kelly, Head of Market Access; Rommel Fernandez, Vice President of Corporate Strategy and Operations; and Kurt Grady, Vice President of Medical Affairs. These hires mark significant milestones in building Alpha Cognition's commercial and medical teams as the company prepares for the upcoming launch of ZUNVEYL, its innovative treatment for mild to moderate Alzheimer's disease. Ms. Pesa brings 25 years of pharmaceutic

    1/14/25 8:30:00 AM ET
    $ACOG

    $ACOG
    Financials

    Live finance-specific insights

    View All

    Alpha Cognition Inc. Reports First Quarter 2026 Financial Results and Provides Operational Update

    ZUNVEYL generated net product revenue of $3.5 million in Q1 2026, a 40% quarter-over-quarter increase Cumulative net product revenue totaled $10.3 million through first four full quarters of launch Q1 2026 bottles dispensed increased 23% quarter-over-quarter to 6,054, with March representing the strongest month of demand since launch Approximately 75% of prescribers and 81% of facilities demonstrated repeat utilization, reinforcing durable adoption trends Real-world clinical studies active, with BEACON enrolling ahead of schedule Cash and cash equivalents totaled $54 million as of March 31, 2026, supporting the Company's continued target of operating profitability in 2027 Compan

    5/14/26 4:15:00 PM ET
    $ACOG

    Alpha Cognition (Nasdaq: ACOG) to Report First Quarter 2026 Financial Results and Provide Business Update on Thursday, May 14, 2026

    Management to host conference call on Thursday, May 14, 2026 at 4:30pm ET Alpha Cognition Inc. (NASDAQ:ACOG), a biopharmaceutical company dedicated to advancing treatments for neurodegenerative diseases, today announced that it will report its first quarter 2026 financial results and provide a business update on Thursday, May 14, 2026, at 4:30 p.m. ET, after market close. The company will issue a press release detailing its first quarter financial results and business highlights on that date. The financial results and accompanying materials will be available in the News section of the Alpha Cognition website at www.alphacognition.com/investors/news/. Following the release, management

    4/28/26 4:30:00 PM ET
    $ACOG

    Alpha Cognition Inc. Reports Fiscal 2025 Financial Results and Provides Operational Update

    Alpha Cognition generated fourth quarter 2025 ZUNVEYL net product revenue of $2.5 million, contributing to full year 2025 total revenue of $10.2 million Fourth quarter bottles dispensed increased 62% quarter-over-quarter to 4,941, with December representing the strongest month since launch Executed second national PBM contract and initiating three studies to further support ZUNVEYL's positioning in long-term care Alzheimer's patients Cash and cash equivalents totaled $66 million at year-end 2025, supporting the company's continued target of operating profitability in 2027 Company to host conference call and webcast today, March 26, at 4:30 p.m. ET Alpha Cognition Inc. (ACOG: NASDA

    3/26/26 4:01:00 PM ET
    $ACOG